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Abstract
Objective—To estimate the prevalence of premenstrual symptoms in women from the general
population in Southampton, UK, and examine their association with lifestyle factors and
contraceptive usage.
Design—Cross-sectional survey.
Setting—The City of Southampton, UK.
Population—974 women aged 20-34 years (53% of the 1,841 women invited to participate).
Methods—Interviews, questionnaires and completion of a prospective six-week menstrual
symptom diary recording on a daily basis the presence and severity of eleven common
premenstrual symptoms.
Main outcome measures—Premenstrual symptoms were identified from the diaries by two
clinicians who reviewed them independently using a pre-defined algorithm to assess the onset and
decline of symptoms in relation to the start of menstruation.
Results—24% of the women were considered to have premenstrual symptoms (95% confidence
interval [CI] 21% to 27%). Women were less likely to have symptoms if they had higher levels of
educational attainment and suffered less from stress. No associations were found between
premenstrual symptoms and diet, alcohol or strenuous exercise, nor after adjustment for other
factors, with age, smoking or body mass index. Use of any form of hormonal contraceptives was
associated with a lower prevalence of premenstrual symptoms (prevalence ratio 0.66 (95%CI:
0.52 to 0.84)).
Conclusions—Premenstrual symptoms were common in this cohort. Use of hormonal
contraceptive methods was associated with a lower prevalence of these symptoms.
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Data from the US 2002 National Health Interview Survey indicate that 19% of young
women have premenstrual syndrome (PMS) or other menstrual-related problems1. Women
with PMS often report cyclical symptoms that can either be psychological, such as
irritability, or physical, such as headaches and back pain2. These conditions can impact on
quality of life3, affecting relationships both at work and home2.
Premenstrual symptoms have been linked to anxiety and depression1 and are associated both
with direct medical costs as well as indirect costs due to absenteeism and low productivity in
the workplace3,4. There may be substantial public health implications, as women with
premenstrual symptoms are more likely to smoke tobacco, drink alcohol and be
overweight1.
The etiology of premenstrual symptoms is uncertain. An interaction between the
neuroendocrine system and a woman’s sensitivity to the changes in plasma levels of steroid
hormones such as estradiol and progesterone are thought to be important5. A wide range of
different treatment regimes including lifestyle, complementary and drug therapies have been
advocated for the specific disorders of premenstrual syndrome (PMS) and premenstrual
dysphoric disorder (PMDD)6-8. Examples of complementary therapies include Vitamin B69
and cognitive behavior therapy10. Selective serotonin reuptake inhibitors have been shown
to be effective given both continuously and cyclically11,12. Cyclical progesterone therapy
has been advocated13 but multiple trials and meta-analyses have shown progesterone to be
ineffective14,15, although these studies mainly looked at cyclical use of progesterone rather
than continuous use. Estrogen, delivered either as patches or implants has been shown in
several studies to help PMS16,17. In addition, recent studies have shown a positive outcome
with combined oral contraceptives containing drospirenone given either cyclically or as a
168 day extended regime18-20.
The Southampton Women’s Survey21 (SWS) is a study of 12,500 young women primarily
aimed at unraveling the determinants of the growth and development of their children. Data
have been collected on factors such as employment, socio-demographic status, age,
ethnicity, physical activity and diet. In this sub-study we have used a menstrual symptom
diary in an attempt to identify women within this cohort who have premenstrual symptoms,
and then to search for associations with lifestyle factors and contraceptive use.
Materials and Methods
Participants in the SWS were recruited via their General Practitioners (GPs), a profession
equivalent to family doctors in the US. A home visit by a research nurse allowed us to
obtain data on sociodemographic status, lifestyle, body composition, educational
qualifications, ethnicity and diet. We also obtained detailed information on contraceptive
use. Following this initial interview, women were invited to provide a blood sample for
measurement of a number of parameters for the main study. In October 2001, towards the
end of the blood-sampling phase, the premenstrual symptoms sub-study was started. All
1,841 women attending from then until the end of the phase in February 2003, were asked
whether they would be interested in taking part in this sub-study. These participants were
asked to complete a six-week menstrual symptom diary (a modified version of the validated
Moos Menstrual Distress Questionnaire22) in addition to the standard interviews and
questionnaires.
Educational grades in the UK are not easily converted to their USA equivalents. We used
five categories of qualifications ranging from category 1 (approximating Grade School),
category 3 (High School Diploma) and category 5 (Bachelor’s Degree or above). Diet in the
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SWS was assessed using a 100-item food frequency questionnaire, previously analyzed
using principal components analysis23. The first principal component can be interpreted as a
summary of the degree to which each woman follows healthy eating recommendations. This
has been termed the ‘prudent diet score’ and is used here to assess associations between
premenstrual symptoms and a healthy diet.
The menstrual questionnaire recorded the presence and severity of 11 common premenstrual
symptoms: irritability, loss of efficiency, difficulty concentrating, tiredness, mood swings,
tension, depression, headaches, food craving, acne and fluid retention (breast tenderness,
weight gain or swollen/bloated). Two GPs (CS and RB) independently assessed these diaries
using criteria developed following a review of definitions of the premenstrual syndrome and
premenstrual dysphoric disorder2,24.
Our definition of premenstrual symptoms was made according to the following criteria:
1. a pattern of symptoms occurring in the days leading up to menstruation that
resolved completely or greatly improved by the end of menstruation,
2. an interval of ≥ 7 days before symptoms recurred, and
3. ≥ 5 symptoms scored as mild or moderate or ≥ 2 symptoms scored as severe, with
each symptom following the pattern described above.
The two GPs independently scored each diary as: 1 (no premenstrual symptoms), 2 (possible
symptoms) or 3 (definite symptoms). Where one scored 3 and the other scored 1, the diary
was reviewed independently by both GPs and their scores revised if appropriate. In cases of
continued disagreement, the GPs met with an arbitrator (HI) to decide on the final score. The
scores from the two GPs were added together giving total scores ranging from 2 to 6.
Women with scores of 5 or 6 were classified as having premenstrual symptoms, while
women with scores equal to or less than 4 were classified as having insufficient symptoms to
meet the case definition. As our method does not consider women over a number of cycles
and we have no information on the effect of symptoms on daily living, our definition does
not conform to formal definitions of premenstrual syndrome7,8,25 and hence our use of the
term ‘premenstrual symptoms’.
The data analysis was performed by examining the differences between women with and
without premenstrual symptoms. Tabulations and Student’s t-tests were used to explore
categorical and continuous variables respectively. Prevalence ratios were calculated using a
generalized linear model with a log link and a binomial error structure (binomial
regression)26. When the prevalence of the outcome is common, odds ratios derived from a
logistic regression cannot be interpreted as approximations to prevalence ratios; this
modeling approach provides direct estimates of prevalence ratios. The risk factors identified
a priori as possibly linked to premenstrual symptoms were age, educational attainment,
smoking status, alcohol consumption, body mass index (BMI), contraceptive use, taking
strenuous exercise, reported level of stress, and the type of diet consumed. These data were
explored initially in a univariate analysis. Subsequently we developed a multiple regression
model by adding variables in a forward step-wise way according to the level of significance
in preceding models. The process was considered complete when no further variables could
be added such that they made a significant contribution to the model at the 5% level.
Results
Of the 1,841 women asked to participate in this study, 974 (53%) returned a menstrual
symptom diary, of which 44 were incomplete and one was found to be outside the age range
for the study. Analysis of the diaries led to identification of premenstrual symptoms in 224
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women (24%, 95% confidence interval [CI] 21 to 27%). These women had a mean GP
coding score of 5.6 compared to a mean score of 2.1 for the remaining women who were
classified as having no premenstrual symptoms. If none of the 912 women who did not
return a complete diary had met the criteria then the prevalence of premenstrual symptoms
in this cohort would have been 12%. We compared the characteristics of responders to the
full SWS study population (Table 1) to look for non-response bias, as women with
premenstrual symptoms may be more likely to participate than non-sufferers. Participants in
this sub-study tended to be somewhat older and better educated than the full study
population but the degree of perceived stress was similar. Slightly more of the responders
were hormonal contraceptive users, but the proportions taking progestins were similar. Such
differences might have a small impact on our overall assessment of prevalence of
premenstrual symptoms but should not unduly affect the internal comparisons examining the
risk factors. For the risk factor analyses we have excluded a further 71 women who had
no discernable menstrual cycle.
In univariate analyses, women with premenstrual symptoms tended to be older, have a lower
level of educational achievement, were more likely to smoke, have a higher body mass
index (BMI), and a higher perceived level of stress (Table 2). There was no significant
difference between those with premenstrual symptoms and those without symptoms with
respect to their ‘prudent diet score’, alcohol intake or level of strenuous exercise (data not
shown).
Premenstrual symptoms were substantially less common in those women currently using
hormonal contraceptives (prevalence ratio 0.63, 95% CI 0.50 to 0.81) (Table 2). Compared
with those not using any form of hormonal contraception, symptoms were less common in
those using noninjectable progestin-only methods, such as the progestin-only pill, the
progestin implant etonogestrel, and the levonorgestrel-releasing intrauterine system
(prevalence ratio 0.54, 95% CI 0.26 to 1.14), and in those using combined (estrogen-
progestin) oral contraceptives (prevalence ratio 0.66, 95% CI 0.52 to 0.84). Premenstrual
symptoms were not identified in any of the nine women using injectable progestins such as
medroxyprogesterone acetate and norethisterone enantate with prevalence ratio 0.0 ([upper]
95% confidence point 1.11).
In a multiple regression model, use of hormonal contraceptives, perceived level of stress,
and educational qualifications remained statistically significant (Table 2), but smoking,
BMI, and age were no longer related to premenstrual symptoms.
In terms of alternative progestins in combined oral contraceptives, only one woman was
taking drospirenone/ethinylestradiol as it was not launched in the UK until 2002 and the low
estrogen-dose variant of drospirenone/ethinylestradiol is not yet in use in the UK.
Discussion
Main findings
We have shown that premenstrual symptoms occur commonly in the Southampton Women’s
Survey cohort (12 - 24% of women aged 20 - 34 years) and these symptoms were linked to
various lifestyle and other factors. In particular high stress, and lower educational
qualifications were associated with increased prevalence of premenstrual symptoms, while
the prevalence was lower in those who used hormonal contraception . Premenstrual
symptoms were more common in those who were older, more obese (also reported by
Strine1 and Hourani27) or who smoked tobacco (also demonstrated by Strine1 and Kritz-
Silverstein28), but such associations were lost when adjusted for contraceptive usage,
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possibly reflecting prescribing practice, such that certain women, for example those who are
obese, may be less likely to be prescribed particular contraceptives.
Comparison with other studies
The associations between premenstrual symptoms, a high perceived level of stress and a low
level of educational achievement have been reported elsewhere1,27. Hourani et al27
specifically focused on job stress in military women but our more general measure of stress,
similar to those used elsewhere1 identifies stress in any area of life as being associated with
premenstrual symptoms. Our lack of an association between diet (measured using the
‘prudent diet score’) and premenstrual symptoms is consistent with the overall findings of
the recent Study of Women’s Health Across the Nation (SWAN), a survey of 3,302 midlife
US women29. This latter study found some links between certain PMS symptoms and
alcohol consumption, in common with other studies1,27, though, we did not find an
association between premenstrual symptoms and alcohol use in our study.
The associations we have described with hormonal contraceptives are intriguing as they are
derived from a large community-based cohort. Some authors argue that contraceptives have
a place in the treatment of PMS30. Notably, three recent studies reported the benefit of
drospirenone-containing combined oral contraceptives in alleviating symptoms of
premenstrual dysphoric disorder either on a 168 extended regime18 or cyclically with a
shorter hormone-free interval than the usual seven days per cycle.19,20,30. In the case of
injectable progestins it must be noted that there have been no formal controlled trials of their
ability to prevent PMS. However, a recent survey of 6,026 US military women27 reported a
strikingly low prevalence of premenstrual symptoms in users of injectable progestins (odds
ratio 0.18, 95% CI 0.10 to 0.32), consistent with our own findings.
Strengths and weaknesses
This was a study of women from the general population, rather than those reporting to
clinics or hospitals with symptoms. While diagnostic criteria have been developed for
specific disorders such as premenstrual syndrome (PMS)7,8,25 and premenstrual dysphoric
disorder (PMDD)24, these focus on diagnosis in a clinical setting and require diaries to be
kept over a number of cycles. This is a challenge in general population research where many
women do not suffer from symptoms and are less motivated to complete diaries over a long
time period, thus biasing the results. We considered that six weeks was the longest time
period for which we could ask women to record symptoms without severely affecting our
response rate. A recent general population study over two menstrual cycles reported a
similar return rate of completed diaries as in our study31. We also were unable to assess the
effect of symptoms on daily living and some women may have been suffering from
premenstrual symptoms that were an exacerbation of another disorder, but the diaries could
not identify this robustly. Thus we do not claim to have assessed PMS according to current
definitions7,8,25, and so have described the condition simply as premenstrual symptoms
throughout.
We studied women from the general population and assessed associations with prevalence
of the symptoms rather than the effect of therapy. Further confounders may be operating in a
number of ways; for example, the need for contraception could indicate a healthier, more
socially engaged population of women who are sexually active and less prone to debilitating
symptoms. However, the symptoms were common in our population and although affecting
quality of life for a few days each month would be unlikely to prevent the women from
leading generally active lives.
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To date the therapeutic trials of hormone treatments for PMS, rather than PMDD as
discussed above, have proved inconclusive14,15,32, but this may be because they assessed
cyclical rather than continuous regimes. Observational evidence from our work and
elsewhere18,27,30,33 suggests that hormonal contraceptive methods that suppress ovulation
and act continuously may have a role in preventing premenstrual symptoms. This provides
some support in favor of large well-powered randomized controlled trials of methods that
induce amenorrhea in the treatment of premenstrual symptoms.
Conclusions
Premenstrual symptoms were common in this cohort of women and occurred more
frequently in those with lower levels of educational attainment and in those who reported
having suffered more from stress. All forms of hormonal contraception were associated with
a lower prevalence of symptoms. The possible protective action of contraceptive methods
that induce amenorrhea and act continuously deserve further study.
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Table 1
Characteristics of the women who completed the menstrual symptom diaries compared with the entire
Southampton Women’s Survey cohort.
Characteristic Those completingmenstrual diaries Entire SWS cohort
1
Age (years)
 <25 142 (15.3%) 3,333 (26.6%)
 25-29 309 (33.3%) 4,319 (34.4%)
 30-34 478 (51.5%) 4,899 (39.0%)
Age at initial interview in years [mean (SD)] 29.6 (3.8) 28.2 (4.2)
Highest educational attainment2 n (%)
 I (lowest level) 106 (11.5%) 2,107 (16.9%)
 2 228 (24.8%) 3,313 (26.5%)
 3 320 (34.7%) 3,729 (29.9%)
 4 54 (5.9%) 724 (5.8%)
 5 (highest level) 213 (23.1%) 2,613 (20.9%)
Number currently smoking (%) 174 (18.8%) 3,858 (30.8%)
BMI kg/m2 [median (interquartile range)] 24.5 (22.3-27.7) 24.1 (21.8-27.5)
Reported extent to which stress has affected life
 None 229 (24.7%) 2,841 (22.7%)
 Slightly 357 (38.4%) 4,721 (37.7%)
 Moderately 183 (19.7%) 2,357 (18.8%)
 Quite a lot 135 (14.5%) 2,131 (17.0%)
 Extremely 25 (2.7%) 468 (3.7%)
Contraceptive type 3
 None 443 (49.1%) 3,096 (51.6%)
 Combined OC 379 (42.0%) 2,359 (39.3%)
 Progestin-only pill, etonogestrel, levonorgestrel 47 (5.2%) 291 (4.9%)
 Injectable progestins 34 (3.8%) 257 (4.3%)
White ethnic group 907 (97.7%) 11,785 (94.1%)
In receipt of social security benefits 128 (13.8%) 2,204 (17.6%)
1
Frequencies do not necessarily sum to the same totals due to missing data.
2
Educational levels are explained in the methods section of the paper.
3
Data on contraceptive type was not requested from the women in the earlier part of the SWS, so these data are only available for 6003 women.
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Table 2
Prevalence of premenstrual symptoms in relation to lifestyle factors in the Southampton Women’s Survey.
Variables are listed where univariate analysis showed a significant association with premenstrual symptoms at
the 5% level of significance. Total numbers studied for each risk factor vary due to missing data. 71 women
with no discernable menstrual cycle have been excluded from the analysis.
Variable Numberstudied
Number and prevalence (%)
of premenstrual symptoms





 <25 133 22 (17%) 1 (baseline)
 25-29 287 78 (27%) 1.64 (1.07 to 2.52)
 30-34 438 124 (28%) 1.71 (1.14 to 2.58)
Ptrend = 0.02
Educational qualifications
 I (lowest level) 98 33 (34%) 1 (baseline) 1 (baseline)
 2 205 59 (29%) 0.85 (0.60 to 1.21) 0.82 (0.58 to 1.15)
 3 297 78 (26%) 0.78 (0.56 to 1.09) 0.75 (0.54 to 1.05)
 4 52 12 (23%) 0.69 (0.39 to 1.21) 0.63 (0.35 to 1.13)
 5 (highest level) 199 41 (21%) 0.61 (0.41 to 0.90) 0.60 (0.40 to 0.88)
Ptrend = 0.01 Ptrend = 0.01
Current smoker
 No 702 172 (25%) 1 (baseline)
 Yes 154 52 (34%) 1.38 (1.07 to 1.78)
BMI group (kg/m2)
 <20 42 7 (17%) 0.67 (0.33 to 1.35)
 20-24.99 435 108 (25%) 1 (baseline)
 25-29.99 230 60 (26%) 1.05 (0.80 to 1.38)
 30-34.99 99 29 (29%) 1.18 (0.83 to 1.67)
 ≥35 44 18 (41%) 1.65 (1.11 to 2.44)
Ptrend = 0.01
Reported extent to which stress has affected life
 None 208 43 (21%) 1 (baseline) 1 (baseline)
 Slightly 333 88 (26%) 1.28 (0.93 to 1.76) 1.42 (1.02 to 1.98)
 Moderately 171 50 (29%) 1.41 (0.99 to 2.01) 1.53 (1.06 to 2.21)
 Quite a lot 122 35 (29%) 1.39 (0.94 to 2.04) 1.54 (1.05 to 2.28)
 Extremely 24 8 (33%) 1.61 (0.86 to 3.01) 1.54 (0.83 to 2.86)
Ptrend = 0.04 Ptrend = 0.03
Use of any hormonal contraceptive
 No 420 133 (32%) 1 (baseline) 1 (baseline)
 Yes 413 83 (20%) 0.63 (0.50 to 0.81) 0.66 (0.52 to 0.84)
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